Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity

David M. Nanus, David P. Kelsen, Roberta Lipperman, Mario Eisenberger

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-two patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (1.50 gm/m2 daily × 5 days) with uroprotective mesna in a phase II study. Eighteen patients were previously untreated. Of 28 evaluable patients, two (7%) had partial remissions lasting 2+ and 6+ months. Toxicity was predominantly myelosuppression with a median WBC nadir of 1.8 cells/ul. Seven patients required hospitalization for nadir sepsis. Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression.

Original languageEnglish (US)
Pages (from-to)239-241
Number of pages3
JournalInvestigational New Drugs
Volume6
Issue number3
DOIs
StatePublished - Sep 1988
Externally publishedYes

Keywords

  • epidermoid carcinoma
  • ifosfamide
  • phase II

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity'. Together they form a unique fingerprint.

Cite this